Nanora Bioscience Corporation pioneers a hydrogel-based siRNA delivery system for targeting PLK1 in cancer therapy. Unlike traditional lipid-based carriers, our chitosan-derived hydrogel technology enhances precision, reduces immune response
risks, and ensures sustained drug release directly to tumor sites.
Designed for PLK1 inhibition in head & neck, lung, and breast cancers.
Overcomes limitations of lipid-based carriers with reliable tumor targeting.
Demonstrated tumor reduction in preclinical and human case studies.
|
Cancer Type
|
Full Name
|
Current Patient (Worldwide )
|
Current Patient (USA)
|
|---|---|---|---|
|
LUSC ,LUAD
|
Lung squamous cell carcinoma,
Lung adenocarcinoma
|
2,480,675
|
226,033
|
|
BRCA
|
Breast invasive carcinoma
|
2,296,840
|
24,7375
|
|
KIRC ,KIRP,KIC
H
|
Kidney renal clear cell
carcinoma, Kidney renal
papillary cell carcinoma, Kidney
chromophobe
|
434,840
|
71,759
H
|
|
HNSC
|
Head and neck squamous cell
carcinoma
|
900,000
|
71,000
|
|
LIHC
|
Liver hepatocellular carcinoma
|
866,136
|
43,492
|
|
UCEC
|
Uterine corpus endometrial
carcinoma
|
324,603
|
21,179
|
|
COAD
|
Colon adenocarcinoma
|
1,926,425
|
160,186
|
|
STAD
|
Stomach adenocarcinoma
|
968,784
|
25,554
|
|
ESCA
|
Esophageal carcinoma
|
511,054
|
18,747
|
|
BLCA
|
Bladder urothelial carcinoma
|
614,298
|
80,404
|
|
PRAD
|
Prostate adenocarcinoma
|
1,467,854
|
230,125
|
|
CHOL
|
Cholangiocarcinoma
|
40,000
|
8,000
|
|
GBM
|
Glioblastoma multiforme
|
400,000
|
30,000
|
|
READ
|
Rectum adenocarcinoma
|
1,926,425
|
160,186
|
|
PAAD
|
Pancreatic adenocarcinoma
|
510,992
|
60,127
|
A Foundation of Trust: At Nanora Bioscience, we’ve built our reputation on a bedrock of trust, earned through years of unwavering commitment to excellence and innovation.
Our commitment to pioneering science ensures we remain at the forefront of medical
advancements.
A patient with head, neck, and lung cancer treated outside the U.S. with our investigational PLK1-suppressing therapy achieved complete remission. While encouraging, this is a single case , not FDA approved, and further studies are ongoing."
We prioritize patient well-being, developing therapies tailored for maximum efficacy and
safety.
Our commitment to ethical practices fosters trust and accountability across all levels.
“Disclaimer:
This website is intended exclusively for accredited investors who have been directly contacted by our team. The information provided on this site is speculative and forward-thinking, reflecting our vision for the future once Nora HNC 1000 is approved. At present, the products and statements discussed have not been clinically tested or approved by the U.S. Food and Drug Administration (FDA) or any other regulatory body. This site is not a solicitation for investment, and access is restricted to those who have been invited to view
Nanora Bioscience Corporation, based in California, is at the forefront of developing, manufacturing, and commercializing innovative siRNA-based cancer therapeutics. Our mission is to leverage cutting-edge technology to target cancer cells, aiming to inhibit tumor growth and transform cancer treatment with patient-focused solutions.
